Similar studies for GEO DataSets (Select 200004170) - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Format

Summary
Summary (text)
Unique Identifier List

Sort by

Default order
Number of Samples (High to Low)
Number of Samples (Low to High)

Send to:

Choose Destination

File
Clipboard
Collections

Links from GEO DataSets

Items: 3

Select item 2000041701.

Gene expression changes associated with progression and response in chronic myeloid leukemia

(Submitter supplied) Chronic myeloid leukemia (CML) is a hematopoetic stem cell disease with distinct biological and clinical features. The biological foundation of the stereotypical progression from chronic phase through accelerated phase to blast crisis is poorly understood. We used DNA microarrays to compare gene expression in 91 cases of CML in chronic (42 cases), accelerated (17 cases), and blast phases (32 cases). more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL2029
119 Samples

Download data: XLS

Series

Accession:: GSE4170

ID:: 200004170

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000490542.

Gene expression changes associated with progression of Irf8–/– CML-like disease into blast crisis after β-catenin activation

(Submitter supplied) Progression and disease relapse of chronic myeloid leukemia (CML) depends on leukemia-initiating cells (LIC) that resist treatment. Using mouse genetics, we observed that compound constitutive activation of β-catenin and deletion of Irf8 results in progression of CML-like disease into fatal blast crisis, elevated leukemic potential of BCR-ABL-induced LICs, and accumulation of Imatinib-resistant LICs in GMP-like populations. more...

Organism:: Mus musculus

Type:: Expression profiling by array

Platform:: GPL11180
11 Samples

Download data: CEL, TXT

Series

Accession:: GSE49054

ID:: 200049054

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000239463.

Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate

(Submitter supplied) The outcome of treating chronic myeloid leukemia (CML) with imatinib mesylate (IM) is inferior when therapy is commenced in late chronic or accelerated phase as compared to early chronic phase. This may be attributed to additional genomic alterations that accumulate during disease progression. We sought to identify such lesions in patients showing suboptimal response to IM by performing array-CGH analysis on 39 sequential samples from 15 CML patients. more...